İzgi ALNIAK, Sevinç ULUSOY, Berkay Arda CEBECİ

The use of methamphetamine in the probation population

Objective: Our research aimed to determine the frequency of methamphetamine use among people referred to health institutions for treatment with the probation decision and to reveal the sociodemographic and clinical profile of people who use methamphetamine. Method: Four hundred and forty-two consecutive cases between 18 and 65 years of age who were referred for treatment to the Probation Outpatient Clinic in Bakirkoy Prof. Mazhar Osman Training and Research Hospital for Psychiatry, Neurology, and Neurosurgery were included in the study. Sociodemographic and clinical information of the cases, substance use and treatment histories, and criminal histories were recorded and evaluated with a semi-structured form. Urine toxicology results, which were taken as one of the obligations of the probation treatment program, were examined. Results: Substance metabolites were detected in the urine toxicological analysis of 81% of the cases. Methamphetamine use was detected in 24.4% of the sample. It was the second most common illicit substance after cannabis and the fourth common seized. Inhalation was the most common method of methamphetamine use. Of the cases still using methamphetamine, 90.7% (n=98) were found to use at least one substance other than methamphetamine. Emergency admissions for substance-related problems, inpatient addiction treatment, outpatient psychiatric treatment, and forensic histories were significantly higher in the group with methamphetamine use than in the group without methamphetamine use. Conclusion: Our study is the first to evaluate the rate of methamphetamine use in the probation population and the sociodemographic and clinical profile of people with methamphetamine use. According to the data obtained, one-fourth of the probation population was using methamphetamine. This group represented a more criminally engaged subgroup of substance users with more inpatient addiction treatment and outpatient psychiatric treatment needs with a high rate of polysubstance use. Recognizing the profile of methamphetamine users is essential to develop strategies to meet their treatment needs. In addition, a probation program might provide an opportunity to raise awareness of substance-related medical and social problems and to motivate individuals who are relatively less engaged with treatment to initiate a therapeutic process.

PDF

___

1. Turkish Penal Code, https://www.mevzuat.gov.tr/ MevzuatMetin/1.5.5237.pdf. Accessed March 17, 2022. [Turkish]
2. Oncu F, Can FY. The practical reflection of alcohol and substance use disorder in judicial processes. In: Basic Reference Book on Alcohol and Substance Use Disorders. Evren C (editor). Istanbul: Turkish Psychiatric Association Study Units Series 24, 2019. [Turkish]
3. Webster JM, Dickson MF, Saman DM, Mateyoke-Scrivner A, Oser CB, Leukefeld C. Substance use, criminal activity, and mental health among violent and nonviolent rural probationers. J Addict Offender Couns 2010; 30:99–111.
4. Yazici AB, Yazici E, Kumsar NA, Erol A. Addiction profile in probation practices in Turkey: 5-year data analysis. Neuropsychiatr Dis Treat 2015; 11:2259–2263.
5. Mutlu E, Alniak I, Aksoy UM, Erkiran M. The use of synthetic cannabinoids among probation population. J Forensic Med 2015; 29:169–178.
6. European Drug Report 2021: Trends and developments. https://www.emcdda.europa.eu/publications/edr/trendsdevelopments/ 2021_en. Accessed March 17, 2022.
7. World Drug Report 2021. https://www.unodc.org/unodc/en/ data-and-analysis/wdr2021.html
8. Turkish Drug Report 2021: Trends and developments. http:// www.narkotik.pol.tr/kurumlar/narkotik.pol.tr/TUBİM/2021- TURKISH-DRUG-REPORT.pdf. Accessed March 17, 2022.
9. Kohno M, Beste C, Pilhatsch M. Editorial: The global methamphetamine problem: approaches to elucidate the neurobiology, epidemiology, and therapeutic effectiveness. Front Psychiatry 2020; 11:850.
10. Chen T, Spiller HA, Badeti J, Funk AR, Zhu M, Smith GA. Methamphetamine exposures reported to United States poison control centers, 2000-2019. Clin Toxicol (Phila) 2021; 59:705– 714.
11. Chiang M, Lombardi D, Du J, Makrum U, Sitthichai R, Harrington A, et al. Methamphetamine-associated psychosis: clinical presentation, biological basis, and treatment options. Hum Psychopharmacol 2019; 34:e2710.
12. Vivolo-Kantor AM, Hoots BE, Seth P, Jones CM. Recent trends and associated factors of amphetamine-type stimulant overdoses in emergency departments. Drug Alcohol Depend 2020; 216:108323.
13. European Drug Report 2019: Trends and developments. https://www.emcdda.europa.eu/publications/edr/trendsdevelopments/ 2019_en. Accessed March 17, 2022.
14. Wilkerson RG, Kim HK, Windsor TA, Mareiniss DP. The opioid epidemic in the United States. Emerg Med Clin North Am 2016; 34:e1–e23.
15. Guy Jr GP, Zhang K, Bohm MK, Losby J, Lewis B, Young R, et al. Vital signs: changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep 2017; 66:697–704.
16. Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend 2018; 193:14–20.
17. Strickland JC, Stoops WW, Dunn KE, Smith KE, Havens JR. The continued rise of methamphetamine use among people who use heroin in the United States. Drug Alcohol Depend 2021; 225:108750.
18. Timko C, Han X, Woodhead E, Shelley A, Cucciare MA. Polysubstance use by stimulant users: health outcomes over three years. J Stud Alcohol Drugs 2018; 79:799–807.
19. Harnett JT, Dargan PI, Dines AM, Archer JRH, Greene SL, Hunter LJ, et al. Increasing emergency department attendances in central London with methamphetamine toxicity and associated harms. Emerg Med J 2021; emermed-2020-209550. [Online ahead of print]
20. Romann V, Illgen M, Derungs A, Klukowska-Rötzler J, Ricklin ME, Exadaktylos A, et al. Presentations with reported methamphetamine use to an urban emergency department in Switzerland. Swiss Med Wkly 2021; 151:w30099.
21. Aldemir E, Berk G, Coskunol H. The effects of the addiction programme of probation on treatment motivation, abstinence and quality of life: a comparative study with motivational interviewing and individual intervention. Noro Psikiyatr Ars 2018; 55:261–270.
22. Cumming C, Troeung L, Young JT, Kelty E, Preen DB. Barriers to accessing methamphetamine treatment: a systematic review and meta-analysis. Drug Alcohol Depend 2016; 168:263–273.
23. Bach P, Hayashi K, Milloy M-J, Nosova E, Kerr T, Wood E, et al. Characterising the increasing prevalence of crystal methamphetamine use in Vancouver, Canada, from 2006-2017: a gender-based analysis. Drug Alcohol Rev 2020; 39:932–940.
24. Kaye S, Lewandowski A, Bowman J, Doyle MF. Crystal methamphetamine use among young people entering custody: prevalence, correlates and comorbidity. Drug Alcohol Rev 2021; 40:1266–1274.
25. Palamar JJ, Han BH, Keyes KM. Trends in characteristics of individuals who use methamphetamine in the United States, 2015-2018. Drug Alcohol Depend 2020; 213:108089.
26. Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults. JAMA Psychiatry 2021; 78:1329–1342.
27. Li MY, Alba GA, Mitton J, Bearnot B. Care-engaged individuals with polysubstance use in Northeastern US are undertreated for methamphetamine use disorder: a retrospective cohort study. Addict Sci Clin Pract 2021; 16:57.
28. Sibanda NC, Kornhaber R, Hunt GE, Morley K, Cleary M. Prevalence and risk factors of emergency department presentations with methamphetamine intoxication or dependence: a systematic review and meta-analysis. Issues Ment Health Nurs 2019; 40:567– 578.
29. Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants-United States, 2015- 2016. MMWR Morb Mortal Wkly Rep 2018; 67:349–358.
30. Al-Tayyib A, Koester S, Langegger S, Raville L. Heroin and methamphetamine injection: an emerging drug use pattern. Subst Use Misuse 2017; 52:1051–1058.
31. Strickland JC, Havens JR, Stoops WW. A nationally representative analysis of "twin epidemics": rising rates of methamphetamine use among persons who use opioids. Drug Alcohol Depend 2019; 204:107592.
32. Miller J, Atala R, Sarangarm D, Tohen M, Sharma S, Bhatt S, et al. Methamphetamine abuse trends in psychiatric emergency services: a retrospective analysis using big data. Community Ment Health J 2020; 56:959–962.
33. Deng H, Verrico CD, Kosten TR, Nielsen DA. Psychosis and synthetic cannabinoids. Psychiatry Res 2018; 268:400–412.
34. Unadkat A, Subasinghe S, Harvey RJ, Castle DJ. Methamphetamine use in patients presenting to emergency departments and psychiatric inpatient facilities: what are the service implications? Australas Psychiatry 2019; 27:14–17.
35. Chan B, Freeman M, Kondo K, Ayers C, Montgomery J, Paynter R, et al. Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis. Addiction 2019; 114:2122–2136.
36. Frost MC, Lampert H, Tsui JI, Iles-Shih MD, Williams EC. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review. Addict Sci Clin Pract 2021; 16:62.
37. Shearer RD, Howell BA, Bart G, Winkelman TNA. Substance use patterns and health profiles among US adults who use opioids, methamphetamine, or both, 2015-2018. Drug Alcohol Depend 2020; 214:108162.
38. Bartholomew TS, Tookes HE, Bullock C, Onugha J, Forrest DW, Feaster DJ. Examining risk behavior and syringe coverage among people who inject drugs accessing a syringe services program: a latent class analysis. Int J Drug Policy 2020; 78:102716.
39. Moradi G, Hajarizadeh B, Rahmani K, Mohamadi-Bolbanabad A, Darvishi S, Zareie B, et al. Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran. Int J Drug Policy 2019; 73:129–134.
40. Stone KA. Reviewing harm reduction for people who inject drugs in Asia: the necessity for growth. Harm Reduct J 2015;12:32.
41. Jarlais DCD. Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduct J 2017; 14:51.